Processa Pharmaceuticals, Inc. — Director's Dealing 2022

Jan 6, 2022

SEC Form 4/A — Form 4/A

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2021-09-30

Reporting Person: Stanker James H (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-30	Restricted Stock Units	$0	A	6024	Disposed		Common Stock (6024)	Direct

Footnotes

F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F2: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance.